Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which ...

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the ...

Sanofi (NASDAQ:SNY) said Wednesday it agreed to acquire clinical-stage biotechnology company Vigil Neuroscience (NASDAQ:VIGL) ...

Deal includes VG-3927, a first-in-class TREM2 agonist aimed at advancing next-generation Alzheimer disease therapies.

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

Part of the deal also includes an additional $2 cash payment per share upon the first commercial sale of Vigil’s Alzheimer’s ...

Key Takeaways Vigil Neuroscience shares more than tripled Thursday after the company reached a deal to be acquired by ...

French pharma Sanofi has acquired the U.S.-based biotech firm Vigil Neuroscience for $470 million, aiming to bolster its ...

About a year after investing in Vigil Neuroscience Inc., Sanofi is now acquiring the Watertown biotech and its treatment in ...

While Vigil stock rocketed upward on the news, Sanofi shares dipped slightly in midday trading, reflecting investor caution ...